Published in
BMJ Publishing Group, Annals of the Rheumatic Diseases, 2(79), p. e14-e14, 2018
DOI: 10.1136/annrheumdis-2018-214788
Links
Tools
Response to: ‘Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching’ by Cantini and Benucci
Journal article published in 2018 by
Bente Glintborg,
Anne Gitte Loft 
,
Emina Omerovic,
Oliver Hendricks,
Asta Linauskas,
Jakob Espesen,
Kamilla Danebod,
Dorte Vendelbo Jensen,
Henrik Nordin,
Emil Barner Dalgaard,
Stavros Chrysidis,
Salome Kristensen,
Johnny Lillelund Raun,
Hanne Lindegaard,
Natalia Manilo
and other authors.
,
Emina Omerovic,
Oliver Hendricks,
Asta Linauskas,
Jakob Espesen,
Kamilla Danebod,
Dorte Vendelbo Jensen,
Henrik Nordin,
Emil Barner Dalgaard,
Stavros Chrysidis,
Salome Kristensen,
Johnny Lillelund Raun,
Hanne Lindegaard,
Natalia Manilo
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 